Table 3.
Safety summary across the entire 260‐week treatment perioda
| Category | Any Secukinumab Dose (N = 587) |
|---|---|
| Exposure to treatment – d, mean (SD) | 1443.6 (616.7) |
| Death, n (%) | 6 (1.0) |
| Discontinued due to AEs, n (%) | 49 (8.3) |
| Any AE | 126.7 |
| Serious AEs | 7.5 |
| Most Common AEs | |
| Nasopharyngitis | 8.6 |
| Upper respiratory tract infection | 8.0 |
| AEs of special interest | |
| Serious infections | 1.8 |
| Candida infections | 0.9 |
| Crohn's disease | 0.2 |
| MACE | 0.5 |
| Malignancies | 0.8 |
Abbreviation: AE, adverse event; EAIR, exposure‐adjusted incidence rate; MACE, major adverse cardiac event.
a
Data are EAIR, unless otherwise stated.